Drugs

New Trial for Combination Therapy

The TTT-1 trial will begin in Scotland early in 2020 to assess a new combination therapy using insulin, dapagliflozin, and semaglutide. It is being led by Dr John Petrie from the University of Glasgow, a leading expert in the treatment of type 1 diabetes. The trial hopes the treatment will become a new option for […]

New Once-Daily Diabetes Pill

Qternmet XR is a single, once daily oral tablet made of dapagliflozin, saxagliptin, and metformin. Results show that the combination of dapagliflozin and saxagliptin have improved glycemic outcomes when added to metformin in patients with diabetes as compared to either drug alone added to metformin. Adverse effects are similar to those of the individual medications. […]

First Oral GLP-1 For Type 2 Diabetes: Rybelsus

Oral semaglutide, brand name Rybelsus, is the first GLP-1 agonist that can be taken by mouth rather than requiring an injection. Studies have shown a significant reduction in A1c, a reduction in cardiovascular disease, and a reduction in weight, without the risk of hypoglycemia, for this drug. Patients must carefully follow instructions for taking the […]

FDA Approval of Invokana for Kidney Disease “First Major Breakthrough in 20 Years”

The FDA has approved a new treatment of Invokana for diabetic chronic kidney disease (CKD), which affects one in three patients with type 2 diabetes. CKD increases the risk for serious cardiovascular events and end-stage renal disease in patiens with type 2 diabetes. The approval of Invokana meets a 20 year need for therapy to […]

Type 1 Cannabis Users at Greater Risk for Ketoacidosis

Adults with type 1 diabetes who use cannabis products are more than twice as likely to develop diabetic ketoacidosis as non-cannabis users with type 1, according to a recent study. The researchers say increased appetite due to cannabis use may be a factor, along with impaired ability to manage diabetes. Read more

FDA Approves New Indication for Invokana

The FDA has approved a new treatment of the diabetes drug Invokana for diabetic kidney disease, which affects one in three patients with type 2 diabetes and increases the risk for serious cardiovascular issues and kidney failure. Read more

Liraglutide and Gall Bladder Issues

In addition to glycemic control, liraglutide also promotes weight loss, which can be helpful in patients with obesity and type 2 diabetes. However, development of gallstones may be a common side effect in patients that are on liraglutide for the treatment of their type 2 diabetes. Read more

FDA Approves Oral Semaglutide for Type 2 Diabetes

The U.S. Food and Drug Administration (FDA) has approved a new medication, Rybelsus (semaglutide) oral tablets, for use in controlling blood sugar in adults with type 2 diabetes, along with diet and exercise. Rybelsus is the first medication in the glucagon-like peptide (GLP-1) receptor class that does not need to be injected to be approved […]

Two Diabetes Drugs Show Benefits for Nonalcoholic Fatty Liver Disease

Nonalcoholic fatty liver disease (NAFLD) often occurs in patients with type 2 diabetes. A recent study showed that the diabetes medications liraglutide and sitagliptin, in combination with metformin, can improve intrahepatic lipid and therefore benefit NAFLD. Read more

Metformin Lowers Risk of Dementia for Black Patients

Researchers found that metformin use was associated with a substantially lower risk for dementia among younger African-American patients with diabetes when compared with sulfonylurea, according to a recently published study. Read more

New Type of Diabetes Drug Performs Well in Phase 3 Trial

Imeglimin is the first in a new class of oral antidiabetic agents, the glimins. Imeglimin decreases hepatic glucose production, increases muscle glucose uptake, and improves pancreatic glucose-dependent insulin secretion. The drug performed well in combination with metformin in its latest trial. Read more

Remission of Type 2 Diabetes

The results of a major study show that intensive weight management strategies and drug therapy can achieve remission of type 2 diabetes. Patients who once suffered may be able to regain their previous quality of life and reduce their risk of secondary complications later down the line. Read more

FDA Approves Victoza for Treating Diabetes in Children

The U.S. Food and Drug Administration (FDA) has approved Victoza (liraglutide) injection for treatment of pediatric patients 10 years or older with type 2 diabetes. Victoza is the first non-insulin drug approved to treat type 2 diabetes in pediatric patients since metformin was approved for pediatric use in 2000. Victoza has been approved to treat […]

Old Malaria Drug May Help Manage Glucose

Hydroxychloroquine is an anti-inflammatory drug that is among the oldest prescribed drugs first used to treat malaria. Researchers have found it may help treat autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis (RA); now, researchers say it can also help with blood glucose management in diabetes. Read more

A Drug to Delay Type 1?

Scientists have reported a major breakthrough in treating type 1 diabetes: a drug that can delay the development of the disease in young people at high risk. The researchers found that 2 weeks of treatment with an experimental intravenous drug delayed development of type 1 diabetes by an average of about two years. Read more

Metformin Associated with B12 Deficiency, Cognitive Issues

A recent study found  that metformin use was associated with impaired cognitive performance and vitamin B12 deficiency. Vitamin B12 and calcium supplements may help to reduce metformin-induced vitamin B12 deficiency, and were associated with better cognitive outcomes in older patients taking metformin. Read more

Some Diabetes Drugs Linked to Genital Gangrene

The SGLT2 inhibitors class of diabetes drugs appear to increase the risk of gangrene of the genital area, a rare but potentially fatal side effect. The FDA found 55 cases of the condition, called Fournier gangrene, in people taking three common types of SGTL2 inhibitors, between March 2013 and January 2019. Read more

Prostrate Drugs May Increase Type 2 Risk

Results from a new study led by the University of Edinburgh and UCL suggests men taking the medicines dutasteride or finasteride to reduce the symptoms of prostate disease may be more likely to develop type 2 diabetes. Read more

Common Prostate Medications May Increase Diabetes Risk

Two widely used drugs for treating an enlarged prostate may increase the risk of developing type 2 diabetes. A study examined of two similar drugs, finasteride (Proscar) and dutasteride (Avodart), in 39,000 men; the 11-year study used 16,000 men taking tamsulosin (Flomax), a different type of drug for B.P.H., as controls. Compared with those using […]

Canagliflozin Study Stopped Early Due to Positive Results

Clinical trials are really stopped early, but the phase 3 trial of “Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation” a.k.a. CREDENCE, was halted early due to demonstration of significant heart and kidney benefits for canagflozin, (Invokana, Janssen Pharmaceuticals Inc.). Read more